UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION~~

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT ~~Pursuant to Section 13 or 15(d) of the~~

~~Securities~~Pursuant ~~Exchange~~to ~~Act~~Section 13 ofor ~~1934~~15(d)

~~Date~~ of ~~Report~~the ~~(Date~~Securities ofExchange ~~earliest~~Act ~~event~~of ~~reported): March 5, 2018~~1934

Date of Report (Date of earliest event reported): March 12, 2018

ANTHERA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-34637	20-1852016	~~20-1852016~~
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)	~~(I.R.S. Employer Identification No.)~~
25801 Industrial Boulevard, Suite B, Hayward, California		94545
(Address of Principal Executive Offices)		(Zip Code)


25801 Industrial Boulevard, Suite B, Hayward, California		94545
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (510) 856-5600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Indicate~~Item ~~by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230~~8.~~405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240~~01.~~12b-2). Emerging~~ ~~growth~~Other ~~company ☐~~Events.

IfOn anMarch ~~emerging~~12, ~~growth~~2018, ~~company~~Anthera Pharmaceuticals, ~~indicate~~Inc. by(the ~~check~~“Company”) ~~mark~~issued ifa ~~the~~press ~~registrant~~release ~~has~~announcing ~~elected~~top ~~not~~line todata ~~use~~from the ~~extended~~Phase ~~transition~~3 ~~period~~RESULT ~~for~~study ~~complying~~of ~~with~~Sollpura ~~any~~in ~~new~~patients orwith ~~revised~~exocrine ~~financial~~pancreatic ~~accounting~~insufficiency. A ~~standards~~copy ~~provided~~of ~~pursuant~~the topress ~~Section~~release ~~13(a)~~is offiled ~~the~~herewith ~~Exchange~~as ~~Act.~~Exhibit ☐99.1.

Item 29.0201. ~~Results~~Financial ofStatements ~~Operations~~ and ~~Financial Conditions~~Exhibits.

~~On March 5, 2018, Anthera Pharmaceuticals, Inc.~~ (~~the “Company”~~d) ~~issued its fourth quarter and year ended December 31, 2017 press release~~Exhibits. ~~A copy of the press release is furnished herewith as Exhibit 99.1~~

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description

99.1		Press release dated March 12, 2018

(d) Exhibits

Exhibit No.			Description
99.1		Press Release dated March 5, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 5, 2018	Anthera Pharmaceuticals, Inc.
Date: March 12, 2018	Anthera Pharmaceuticals, Inc.
	By:	/s/ ~~May~~J. ~~Liu~~Craig Thompson
		May Liu Senior Vice President, Finance and Administration (Principal Accounting Officer)
		J. Craig Thompson
		President and Chief Executive Officer (Principal Executive Officer)

Exhibit Index


Exhibit No.		Description

99.1		Press release dated March 12, 2018

Filing Compare · Anthera Pharmaceuticals Inc